April 7, 2020 - Toronto - POINT Biopharma Inc. is pleased to announce theformation of its global prostate oncology therapeutic advisory board.
The Board, comprised of leading global experts in scientific discovery and clinical leadership, will provide guidance, product input, and thought leadership on oncology trends and radiopharmaceutical development.
"We are very pleased with the exceptional composition of the new Global Advisory Board," stated Dr. Neil Fleshner, POINT Biopharma’s Chief Medical Officer. "I am honored to partner with these leading innovators to help guide POINT and bring our innovation into clinical settings this year.”
The POINT Biopharma Global Advisory Board members include:
Dr. Kim Chi, Advisory board chair adds, “I am looking forward to working on the development of POINT’s clinical program and bringing these innovative next generation products to my patients.”